目前，科创板与主板各贡献一家费用率在20%以上的企业，其中赛分科技以23.2%的费用率高居榜首 ——根据数据，赛分科技首发募资额接近2.16亿元，发行费用合计5009.37万元。 年内中信证券被监管数次"点名"。今年5月14日，上交所发布监管措施决定书表示，中信证券作为相关 上市公司再融资项目的保荐人，李宁、吴鹏、黄艺彬、李婉璐作为中信证券指定的项目保荐代表人，存 在保荐职责履行不到位的情形，对此负有直接责任。 【深圳商报讯】(记者詹钰叶)今年以来A股新增首发企业超100家，合计募资超过1100亿元，发行总费用 合计近81亿元，占比超7%。其中，赛分科技发行费用占募资额的比例高达23.2%，位居榜首。其保荐机 构中信证券年内在首发项目上获得的承销与保荐费收入同比翻倍，但也因投行违规被监管点名。 ...

有业内人士表示，赛分科技扬州二期工程将进一步强化对合作伙伴的服务能力，提升规模化交付效率，持续提供稳定可靠 的产品及配套服务，为合作伙伴各项目稳定生产与产能扩张保驾护航。同时，伴随中国生物制药出海浪潮，该项目也将助力公 司推进海外市场拓展战略，进一步扩大赛分科技在全球色谱层析市场的影响力。 （编辑 郭之宸） 据悉，作为国产色谱填料龙头企业，赛分科技深度参与中国生物医药行业快速发展及供应链国产化进程，在抗体、胰岛 素、GLP-1等多肽药物、重组蛋白、核酸药物等生物药细分领域积累了广泛应用项目，其中临床后期及商业化项目数量超百 个。公司与生物药各领域标杆企业紧密合作，部分重点项目中填料单次供货量超千升，最大达4000升，Protein A亲和、定制亲 和、阴阳离子交换、疏水等填料的装柱规模均达到2000mm。面对持续增长的色谱填料规模化供应需求，扬州二期项目配置 5000L最大反应釜，单批次产能超1000L，同时升级自动化生产管理系统与质量管理系统，将进一步提升赛分科技色谱填料规模 化供应能力及产品质量管理水平。 赛分科技自上市以来，业务发展态势强劲。2025年前三季度，公司实现营业收入3.02亿元，同比增长38 ...

近期，中国生物医药行业发展迅速，夏尔巴生物成功完成全国首批2万升规模抗体生产，信达生物达成 重磅BD交易，加速迈向全球市场，甘李药业签署巴西国家级《技术转移与供应协议》，百奥泰 Usymro®获欧盟委员会上市批准，安睿特重组人白蛋白注射液Ⅲ期临床试验完成揭盲，这些赛分科技合 作伙伴的商业化能力不断加强，意味着对高性能表现、大规模供应、高质量水平的国产色谱填料的需求 也将迅速和持续增加。赛分科技扬州二期工程将更好地服务合作伙伴，提升规模化交付能力，持续提供 稳定可靠的产品和配套服务，为合作伙伴各项目的稳定生产和产能增长保驾护航。同时，伴随着中国生 物制药的出海大潮，扬州二期工程也将支持公司扩展海外市场的发展战略，扩大赛分科技在全球色谱层 析市场的影响力。（齐和宁） 赛分科技于今年一月登陆科创板，上市以来，整体业务发展态势强劲，2025年前三季度实现营业收入 3.02亿元，同比增长38.39%，归属于上市公司股东的净利润9321.18万元，同比增长71.07%，其中，工 业纯化板块增长尤为显著，2025年前三季度收入同比增长68.08%。在产能布局方面，作为上市募投项 目的扬州二期工程已全面启动建设，这一举措不仅 ...

大牛股再度涨停。 12月5日早盘，A股三大股指盘中窄幅震荡上扬，临近午盘发力拉升，沪指翻红。截至午间收盘，沪指微涨0.08%报3878.99点，深证成指涨0.39%，创业板指涨 0.47%，沪深北三市合计成交9996亿元。 盘面上，市场现明显分化，银行、地产、医药等板块疲弱；商业航天概念再度活跃，超捷股份20%涨停；CPO概念拉升，长光华芯涨停创历史新高，东田微、炬光 科技、太辰光等涨超10%；特高压概念崛起，红相股份、特发信息涨停，太阳电缆斩获4连板；福建本地股再度爆发，三木集团、舒华体育、安记食品等涨停。此 外，合富中国（603122）再度涨停，在近26个交易日内斩获15个涨停板。 值得注意的是，今日登陆科创板的摩尔线程早盘一度涨超500%最高攀升至688元/股，单签最高盈利超28万元。 商业航天概念活跃 商业航天概念再度活跃，截至午间收盘，超捷股份20%涨停，星环科技涨超15%，天箭科技、航天科技等多股亦涨停。 | 代码 | 名称 | ﻬ | 涨幅% | 现价 | 涨跌 | 买价 | 卖价 | 总量 | | --- | --- | --- | --- | --- | --- | --- | --- | ...

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Group 1 - The core viewpoint of the news is that Sai Fen Technology has shown a mixed performance in financing activities, with a net financing outflow on November 20, 2023, and a significant increase in revenue and profit year-on-year for the first nine months of 2025 [1][2]. Group 2 - On November 20, 2023, Sai Fen Technology's stock price increased by 0.70%, with a trading volume of 71.15 million yuan. The financing buy-in amount was 4.03 million yuan, while the financing repayment was 12.21 million yuan, resulting in a net financing outflow of 8.19 million yuan [1]. - As of November 20, 2023, the total balance of margin trading for Sai Fen Technology was 77.28 million yuan, accounting for 8.48% of its circulating market value [1]. - The company reported a revenue of 302 million yuan for the period from January to September 2025, representing a year-on-year growth of 38.39%. The net profit attributable to the parent company was 93.21 million yuan, reflecting a year-on-year increase of 71.07% [2]. - The main business segments of Sai Fen Technology include industrial purification (33.10%), industrial purification: fillers (32.65%), analytical chromatography (16.73%), and others [2]. - As of September 30, 2025, the number of shareholders was 7,159, a decrease of 31.51% from the previous period, while the average circulating shares per person increased by 57.01% to 5,933 shares [2].

Group 1 - The core point of the news is that Saifen Technology has seen a stock price increase of 5.51%, reaching 23.36 CNY per share, with a total market capitalization of 9.729 billion CNY [1] - Saifen Technology, established on March 16, 2009, specializes in the research and production of liquid chromatography materials for drug analysis and purification [1] - The company's main business revenue breakdown includes: Industrial Purification Segment 33.10%, Industrial Purification Fillers 32.65%, Analytical Chromatography Segment 16.73%, Analytical Chromatography Columns 13.31%, Analytical Chromatography Fillers 3.13%, and other segments contributing smaller percentages [1] Group 2 - According to data, one fund from GF Fund has Saifen Technology as its second-largest holding, with 777 shares held unchanged from the previous period [2] - The fund, GF CSI A500 ETF Link A (022424), has a total scale of 3.321 billion CNY and has achieved a year-to-date return of 23.59% [2] - The fund manager, Lu Zhimin, has a tenure of 14 years and 169 days, with the fund's total asset scale at 24.063 billion CNY [3]

Core Points - The Sci-Tech Innovation Board (STAR Market) index rose by 1.44%, closing at 1399.29 points, with a total trading volume of 4.357 billion shares and a turnover of 189.525 billion yuan [1] - Among the tradable stocks on the STAR Market, 419 stocks closed higher, with 11 stocks experiencing a rise of over 10%, including Kangpeng Technology, Haibo Sichuang, and Huasheng Lithium, which hit the daily limit [1] - The turnover rate for STAR Market stocks showed that 3 stocks had a turnover rate exceeding 20%, while 21 stocks had a turnover rate between 10% and 20% [1] Trading Performance - The highest turnover rate was recorded by Haibo Sichuang at 22.07%, with a closing price increase of 20.00% and a trading volume of 2.869 billion yuan [1][3] - Other notable stocks with high turnover rates included Saifen Technology (21.43% turnover rate, 10.92% increase) and Kangpeng Technology (20.48% turnover rate, 20.02% increase) [3][4] - The stocks with the largest net inflow of funds included Haibo Sichuang (281.31 million yuan), Changguang Huaxin (166.1 million yuan), and Huasheng Lithium (88.835 million yuan) [2] Sector Analysis - In terms of industry distribution, the electronics sector had the most stocks with a turnover rate exceeding 5%, totaling 20 stocks, followed by power equipment and pharmaceutical biotechnology with 18 and 9 stocks, respectively [2] - The stocks with significant net outflows included Artis (454 million yuan), Yuanjie Technology (185 million yuan), and Baiwei Storage (168 million yuan) [2] Recent Trends - As of November 12, the stocks with the largest increase in financing balance over the past five days included Purun Co. (271 million yuan), Yuanjie Technology (252 million yuan), and Shenkong Co. (223 million yuan) [2] - Conversely, the stocks with the largest decrease in financing balance included Foxit Software (192 million yuan), New Xiangwei (184 million yuan), and Jucheng Co. (117 million yuan) [2]

Group 1 - The core viewpoint of the news is that Sai Fen Technology's stock performance and financial metrics indicate a mixed outlook, with a slight decline in stock price and notable financing activities [1][2]. Group 2 - On November 12, Sai Fen Technology's stock price decreased by 0.30%, with a trading volume of 58.96 million yuan. The financing buy-in amount was 4.28 million yuan, while the financing repayment was 6.13 million yuan, resulting in a net financing buy-in of -1.85 million yuan [1]. - As of November 12, the total financing and securities lending balance for Sai Fen Technology was 74.42 million yuan, accounting for 8.78% of its circulating market value [1]. - The company has not engaged in any securities lending activities on November 12, with no shares sold or repaid [1]. Group 3 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2]. - The company's revenue composition includes: Industrial Purification Segment (33.10%), Fillers (32.65%), Analytical Chromatography Segment (16.73%), Chromatography Columns (13.31%), and other minor segments [2]. - For the period from January to September 2025, Sai Fen Technology achieved a revenue of 302 million yuan, representing a year-on-year growth of 38.39%, and a net profit attributable to shareholders of 93.21 million yuan, with a year-on-year increase of 71.07% [2]. Group 4 - Since its A-share listing, Sai Fen Technology has distributed a total of 27.90 million yuan in dividends [3]. - As of September 30, 2025, the number of shareholders decreased by 31.51% to 7,159, while the average circulating shares per person increased by 57.01% to 5,933 shares [2][3].

Group 1 - The core viewpoint of the news highlights the performance and financial metrics of Sai Fen Technology, including stock price increase and trading volume [1] - On November 11, Sai Fen Technology's stock rose by 4.60%, with a trading volume of 102 million yuan and a net financing purchase of 1.7166 million yuan [1] - As of November 11, the total margin balance for Sai Fen Technology was 76.2679 million yuan, accounting for 8.97% of its market capitalization [1] Group 2 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2] - The company's revenue composition includes 33.10% from industrial purification, 32.65% from fillers, and 16.73% from analytical chromatography, among other segments [2] - For the period from January to September 2025, Sai Fen Technology achieved a revenue of 302 million yuan, representing a year-on-year growth of 38.39%, and a net profit of 93.2118 million yuan, with a growth of 71.07% [2] Group 3 - Since its A-share listing, Sai Fen Technology has distributed a total of 27.9031 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders decreased by 31.51% to 7,159, while the average circulating shares per person increased by 57.01% to 5,933 shares [2][3] - Notably, the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund has exited the top ten circulating shareholders list [3]